Niacin

Niacin

SCHEMBL679599

O=C([O-])c1cccnc1.[Cu+]

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
GAA P10253 2/20 0.63
APP P05067 1/20 0.63
HCAR3 P49019 1/20 0.63
HCAR2 Q8TDS4 1/20 0.63
F7 P08709 1/20 0.61
F3 P13726 1/20 0.61
SARM1 Q6SZW1 1/20 0.61
SIRT2 Q8IXJ6 1/20 0.61
SIRT6 Q8N6T7 1/20 0.61
SIRT1 Q96EB6 1/20 0.61
SIRT3 Q9NTG7 1/20 0.61
SIRT5 Q9NXA8 1/20 0.61
SIRT4 Q9Y6E7 1/20 0.61
HDAC1 Q13547 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
PLOD2 O00469 2/20 0.53
LMNA P02545 2/20 0.52
THRB P10828 1/20 0.52
HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niacin SCHEMBL679551 0.98 ALDH1A1 (0.61) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL3498987 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL587526 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL6012008 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL25269786 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL23780930 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL308681 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL1943861 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL10357700 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2
Niacin SCHEMBL987479 0.96 ALDH1A1 (0.63) ALDH1A1GAAAPPHCAR3HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034137-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2026-02-05 US claimed
US-20230149412-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2023-05-18 US claimed
US-20230149488-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2023-05-18 US claimed
US-20230025435-A1 COMPOSITIONS AND METHODS FOR INCREASING CELLULAR VITALITY AND LONGEVITY AND DECREASING MOLECULAR AGEING JUVN3 HOLDINGS, LLC (US) 2023-01-26 US claimed
US-20260034137-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2026-02-05 US disclosed
US-20230149412-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2023-05-18 US disclosed
US-20230149488-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2023-05-18 US disclosed
US-20230025435-A1 COMPOSITIONS AND METHODS FOR INCREASING CELLULAR VITALITY AND LONGEVITY AND DECREASING MOLECULAR AGEING JUVN3 HOLDINGS, LLC (US) 2023-01-26 US disclosed
US-20220288211-A1 DOSAGE-INDICATING TOPICAL FORMULATION AND METHOD OF USING A DOSAGE-INDICATING TOPICAL FORMULATION Younger Phenotype Inc. (US) 2022-09-15 US disclosed
CN-114980906-A Compositions and methods for increasing cell viability and longevity and reducing molecular aging JUVN3控股有限责任公司 2022-08-30 CN disclosed
CN-109123101-B Preparation method of manganese nicotinate 长沙兴嘉生物工程股份有限公司 2022-02-11 CN disclosed
WO-2021141955-A1 COMPOSITIONS AND METHODS FOR INCREASING CELLULAR VITALITY AND LONGEVITY AND DECREASING MOLECULAR AGEING JUVN3 HOLDINGS, LLC (US) 2021-07-15 WO disclosed
US-10258980-B2 Pure chelation process C LAB PHARMA INTERNATIONAL, S.A. (VG) 2019-04-16 US disclosed
US-20170274370-A1 PURE CHELATION PROCESS C LAB PHARMA INTERNATIONAL, S.A. (VG) 2017-09-28 US disclosed
EP-3188835-A1 PURE CHELATION PROCESS C Lab Pharma International, S.A. (VG) 2017-07-12 EP disclosed
CN-105754331-A Polyamide Resin Composition And Molded Article 旭化成株式会社 2016-07-13 CN disclosed
WO-2016037181-A1 PURE CHELATION PROCESS C LAB PHARMA INTERNATIONAL, S.A. (VG) 2016-03-10 WO disclosed
US-20130184247-A1 METHOD FOR PREPARATION OF NICOTINIC ACID COPPER CHLORIDE COMPLEX, AND ITS PHARMACEUTICAL USES HUSSEIN ALY IBRAHEIM SALAH FATHIY (EG) 2013-07-18 US disclosed
US-20110274773-A1 Copper(I) Chloride Complex Of Nicotinic Acid And Pharmaceutical Compositions Containing The Same HUSSEIN ALY IBRAHEIM SALAH FATHIY 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034137-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity TFAM, POT1, CLPX ALDH1A1 2977/4885GAA 463/4885APP 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.